Braeburn Pharmaceuticals Inc., of Princeton, N.J., presented data from a phase III study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, showing that participants who were clinically stable on sublingual buprenorphine maintained stability when transferred to Probuphine and they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine. Data were presented at the American Society of Addiction Medicine conference in Baltimore. Probuphine is under FDA review, with a PDUFA date of May 27.